📊 DTIL Key Takeaways
Is DTIL a Good Investment? Thesis Analysis
Precision Biosciences is in severe financial distress with massive operating losses (-$52.1M), negative free cash flow (-$65.9M), and collapsing revenue (-50.1% YoY). Despite strong liquidity reserves ($110.8M cash), the company is burning cash at an unsustainable rate with no clear path to profitability, indicating a pre-revenue or failed clinical program status typical of troubled biotech firms.
Why Buy DTIL? Key Strengths
- Substantial cash reserves of $110.8M provide 12-18 months of runway at current burn rates
- Strong liquidity position with 13.32x current ratio reduces near-term bankruptcy risk
- Low leverage with 0.24x debt-to-equity ratio limits debt servicing burden
DTIL Investment Risks to Consider
- Catastrophic revenue collapse of 50.1% YoY indicates loss of major contracts or failed product commercialization
- Operating losses of $52.1M with negative margins of -152.2% demonstrate the business model cannot generate positive unit economics
- Cash burn rate of $65.8M annually will deplete reserves in approximately 20 months without additional financing or operational turnaround
- Negative ROE of -49.6% and ROA of -29.6% show shareholder capital is being destroyed at an accelerating rate
Key Metrics to Watch
- Quarterly operating cash flow burn rate and timeline to cash depletion
- Revenue stabilization or recovery in next two quarters; sustained decline signals terminal decline
- Progress on pipeline programs and clinical trial milestones; lack of catalysts increases dilution risk
DTIL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.32x current ratio provides a solid financial cushion.
DTIL Profitability Ratios
DTIL vs Healthcare Sector
How PRECISION BIOSCIENCES INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DTIL Overvalued or Undervalued?
Based on fundamental analysis, PRECISION BIOSCIENCES INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DTIL Balance Sheet & Liquidity
DTIL 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: PRECISION BIOSCIENCES INC's revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $1.04 reflects profitable operations.
DTIL Growth Metrics (YoY)
DTIL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $13.0K | $8.6M | $-1.84 |
| Q2 2025 | $18.0K | $8.6M | $-2.13 |
| Q1 2025 | $29.0K | $8.6M | $1.70 |
| Q3 2024 | $576.0K | -$8.1M | $-2.10 |
| Q2 2024 | $19.8M | $8.6M | $-3.13 |
| Q1 2024 | $8.8M | $8.6M | $1.70 |
| Q3 2023 | $7.4M | -$8.1M | $-0.07 |
| Q2 2023 | $3.8M | -$11.9M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DTIL Capital Allocation
DTIL SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for PRECISION BIOSCIENCES INC (CIK: 0001357874)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DTIL
What is the AI rating for DTIL?
PRECISION BIOSCIENCES INC (DTIL) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DTIL's key strengths?
Claude: Substantial cash reserves of $110.8M provide 12-18 months of runway at current burn rates. Strong liquidity position with 13.32x current ratio reduces near-term bankruptcy risk.
What are the risks of investing in DTIL?
Claude: Catastrophic revenue collapse of 50.1% YoY indicates loss of major contracts or failed product commercialization. Operating losses of $52.1M with negative margins of -152.2% demonstrate the business model cannot generate positive unit economics.
What is DTIL's revenue and growth?
PRECISION BIOSCIENCES INC reported revenue of $34.3M.
Does DTIL pay dividends?
PRECISION BIOSCIENCES INC does not currently pay dividends.
Where can I find DTIL SEC filings?
Official SEC filings for PRECISION BIOSCIENCES INC (CIK: 0001357874) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DTIL's EPS?
PRECISION BIOSCIENCES INC has a diluted EPS of $-3.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DTIL a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, PRECISION BIOSCIENCES INC has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DTIL stock overvalued or undervalued?
Valuation metrics for DTIL: ROE of -49.6% (sector avg: 15%), net margin of -133.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DTIL stock in 2026?
Our dual AI analysis gives PRECISION BIOSCIENCES INC a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DTIL's free cash flow?
PRECISION BIOSCIENCES INC's operating cash flow is $-65.8M, with capital expenditures of $85.0K. FCF margin is -192.4%.
How does DTIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -133.4% (avg: 12%), ROE -49.6% (avg: 15%), current ratio 13.32 (avg: 2).